Prognostic Value of Translationally Controlled Tumor Protein in Colon Cancer

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2023 Aug 24

PMID 37614375

Authors

Dragomir Svetozarov Stoyanov

Nikolay Vladimirov Conev

Mariya Ivanova Penkova-Ivanova

Ivan Shterev Donev

Affiliations

Soon will be listed here.

Abstract

The translationally controlled tumor protein (TCTP) is a highly conserved protein involved in a variety of normal cell functions and disease processes. Preclinical studies revealed that TCTP has anti-apoptotic properties, promotes cell growth and division and is involved in cancer progression by promoting invasion and metastasis. The present study explored the potential value of TCTP as a prognostic marker in colon cancer. A retrospective analysis of 74 patients with colon cancer was performed. Using immunohistochemistry, TCTP levels in the primary tumor were assessed semi-quantitatively by the calculation of cytoplasmic and nuclear H-score. Cytoplasmic TCTP levels in the primary tumor had no statistically significant association with disease-free survival (DFS), progression-free survival (PFS) and overall survival (OS) in the present patient population. Patients whose primary tumors had a negative nuclear TCTP expression had significantly improved clinical outcomes. The PFS for the negative nuclear TCTP expression group was 7.7 months [95% confidence interval (CI), 5.8-9.5] compared with 5.5 months (95% CI, 3.2-7.8) in the group with positive nuclear expression (P=0.023, Mantel-Cox log-rank). Patients with a negative nuclear expression of TCTP had a significantly higher median OS (22.2 months; 95% CI, 16.1-28.3) compared with those with positive TCTP nuclear expression (median 13.2 months; 95% CI, 10.1-16.3; P=0.008, Mantel-Cox log-rank). In a multivariate Cox regression model, a positive nuclear TCTP H-score was an independent risk factor for worse PFS and OS. The 1-year OS rate in the group with negative nuclear TCTP expression was 86.3% compared with 56.5% in patients with positive nuclear TCTP expression (P=0.008). The present study suggested that semiquantitative H-score measurement of TCTP levels in the nuclei of tumor cells from the primary tumor is a potential prognostic marker for clinical outcomes in patients with colon cancer.

References

Ma Q, Geng Y, Xu W, Wu Y, He F, Shu W . The role of translationally controlled tumor protein in tumor growth and metastasis of colon adenocarcinoma cells. J Proteome Res. 2009; 9(1):40-9. DOI: 10.1021/pr9001367. View

Lucibello M, Gambacurta A, Zonfrillo M, Pierimarchi P, Serafino A, Rasi G . TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Exp Cell Res. 2011; 317(17):2479-89. DOI: 10.1016/j.yexcr.2011.07.012. View

Bommer U, Vine K, Puri P, Engel M, Belfiore L, Fildes K . Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun Signal. 2017; 15(1):9. PMC: 5286767. DOI: 10.1186/s12964-017-0164-3. View

Tuynder M, Fiucci G, Prieur S, Lespagnol A, Geant A, Beaucourt S . Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A. 2004; 101(43):15364-9. PMC: 523462. DOI: 10.1073/pnas.0406776101. View

Thaw P, Baxter N, Hounslow A, Price C, Waltho J, Craven C . Structure of TCTP reveals unexpected relationship with guanine nucleotide-free chaperones. Nat Struct Biol. 2001; 8(8):701-4. DOI: 10.1038/90415. View

Rho S, Lee J, Park M, Byun H, Kang S, Seo S . Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett. 2010; 585(1):29-35. DOI: 10.1016/j.febslet.2010.11.014. View

Gnanasekar M, Thirugnanam S, Zheng G, Chen A, Ramaswamy K . Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells. Int J Oncol. 2009; 34(5):1241-6. View

Zhang D, Li F, Weidner D, Mnjoyan Z, Fujise K . Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and Fortilin. The potential role of MCL1 as a fortilin chaperone. J Biol Chem. 2002; 277(40):37430-8. DOI: 10.1074/jbc.M207413200. View

Nielsen H, Johnsen A, Sanchez J, Hochstrasser D, Schiotz P . Identification of a basophil leukocyte interleukin-3-regulated protein that is identical to IgE-dependent histamine-releasing factor. Allergy. 1998; 53(7):642-52. DOI: 10.1111/j.1398-9995.1998.tb03950.x. View

10.

Lucibello M, Adanti S, Antelmi E, Dezi D, Ciafre S, Carcangiu M . Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. Oncotarget. 2015; 6(7):5275-91. PMC: 4467148. DOI: 10.18632/oncotarget.2971. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Telerman A, Amson R . The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat Rev Cancer. 2009; 9(3):206-16. DOI: 10.1038/nrc2589. View

13.

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

14.

Li F, Zhang D, Fujise K . Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem. 2001; 276(50):47542-9. DOI: 10.1074/jbc.M108954200. View

15.

Punt C, Koopman M, Vermeulen L . From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2016; 14(4):235-246. DOI: 10.1038/nrclinonc.2016.171. View

16.

Chan T, Chen L, Guan X . Role of translationally controlled tumor protein in cancer progression. Biochem Res Int. 2012; 2012:369384. PMC: 3337558. DOI: 10.1155/2012/369384. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Kottgen E . Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis. 2000; 21(14):3048-57. DOI: 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W. View

19.

Chen C, Deng Y, Hua M, Xi Q, Liu R, Yang S . Expression and clinical role of TCTP in epithelial ovarian cancer. J Mol Histol. 2015; 46(2):145-56. DOI: 10.1007/s10735-014-9607-y. View

20.

Thiele H, Berger M, Skalweit A, Thiele B . Expression of the gene and processed pseudogenes encoding the human and rabbit translationally controlled tumour protein (TCTP). Eur J Biochem. 2000; 267(17):5473-81. DOI: 10.1046/j.1432-1327.2000.01609.x. View